deltatrials
Completed PHASE1 NCT00408538

Safety and Acceptability Study of the UC-781 Microbicide Gel Applied Rectally

A Phase 1 Randomized, Blinded, Placebo-Controlled Safety and Acceptability Study of the UC-781 Vaginal Microbicide Gel Formulation Applied Rectally in HIV-1 Seronegative Adults

Sponsor: CONRAD

Conditions HIV Infections
Interventions UC-781 microbicide gel (0.1% and 0.25%) placebo
Updated 5 times since 2017 Last updated: May 1, 2009 Started: Dec 31, 2006 Completion: Apr 30, 2008

A PHASE1 clinical study on HIV Infections, this trial is completed. The trial is conducted by CONRAD and has accumulated 5 data snapshots since 2006. Infectious disease trials contribute critical data for public health response and treatment development.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1

    First recorded

Dec 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • CONRAD
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • University of California, Los Angeles
Data source: University of California, Los Angeles

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Los Angeles, United States